KAMADA LTDKMDAEarnings & Financial Report

Nasdaq · pharmaceutical industry

Kamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma.

NextFeb 27, 2026

Revenue

$47.0M

Gross Profit

$19.8M

Operating Profit

$7.8M

Net Profit

$5.3M

Gross Margin

42.0%

Operating Margin

16.6%

Net Margin

11.3%

YoY Growth

12.6%

EPS

$0.09

Financial Flow

KAMADA LTD Q3 2025 Financial Summary

KAMADA LTD reported revenue of $47.0M for Q3 2025, with a net profit of $5.3M (11.3% margin). Cost of goods sold was $27.2M, operating expenses totaled $11.9M.

Key Financial Metrics

Total Revenue	$47.0M
Net Profit	$5.3M
Gross Margin	42.0%
Operating Margin	16.6%
Report Period	Q3 2025

Income Statement

	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$37.4M	$37934	$37736	$42.5M	$41.7M	$44.0M	$44.8M	$47.0M
YoY Growth	58.7%	-99.9%	-99.9%	13.4%	109933.2%	116547.2%	5.4%	12.6%

Balance Sheet

	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$314.4M	$337056	$343174	$351.0M	$351.2M	$375.1M	$368.2M	$377.2M
Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Equity	$176.8M	$238390	$246510	$251.2M	$255.3M	$252.0M	$260.0M	$265.2M